Empiric treatment must not await culture confirmation
Clinical and epidemiological grounds sufficient for initiation
Drug resistance
Natural resistance rare
Most strains remain susceptible to standard agents
Engineered resistance concern
Bioterrorism scenario may involve drug-resistant strains
Broad coverage and dual therapy prudent in bioterrorism context
ICD-10 classification
A20.2: Pneumonic plague
A20.0: Bubonic plague
A20.7: Septicaemic plague
A20.9: Plague, unspecified
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for Plague (Pneumonic)
Medication instructions
Complete the full course of antibiotics as prescribed (10-14 days total)
Do not stop antibiotics even if you feel better
Take doxycycline with a full glass of water and remain upright for 30 minutes
Activity and precautions
Droplet isolation precautions until 48 hours of effective antibiotic therapy completed
Avoid close contact (within 2 metres) with others until cleared by infectious disease
All household contacts must be evaluated by public health for prophylaxis
Return to emergency department immediately if
Difficulty breathing or worsening shortness of breath
Return of high fever despite antibiotics
Coughing up blood
Confusion or altered mental status
Inability to keep medications down
Any new symptoms suggesting clinical deterioration
Follow-up requirements
Infectious disease follow-up within 48-72 hours of discharge
Weekly follow-up until antibiotic course completed
Public health contact tracing coordination
Public health obligations
All household and close contacts must receive prophylactic antibiotics
Notify public health of any new contacts identified
Do not travel or return to work until cleared by infectious disease and public health
References
Guidelines and key sources
Primary guidelines and landmark references
Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response. MMWR Recomm Rep. 2021
Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a Biological Weapon: Medical and Public Health Management. JAMA. 2000;283(17):2281-2290
Randremanana RV, Raberahona M, Bourner J, et al. Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague. N Engl J Med. 2025
Godfred-Cato S, Cooley KM, Fleck-Derderian S, et al. Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939-2019. Clin Infect Dis. 2020
Jullien S, Dissanayake HA, Chaplin M. Rapid Diagnostic Tests for Plague. Cochrane Database Syst Rev. 2020
Prentice MB, Rahalison L. Plague. Lancet. 2007;369(9568):1196-1207
Adalja AA, Toner E, Inglesby TV. Clinical Management of Potential Bioterrorism-Related Conditions. N Engl J Med. 2015;372(10):954-962
Ratsitorahina M, Chanteau S, Rahalison L, et al. Epidemiological and Diagnostic Aspects of the Outbreak of Pneumonic Plague in Madagascar. Lancet. 2000;355(9198):111-113
Wang W, Li X, Wu J, et al. Imaging Analysis of Pneumonic Plague Infection in Xizang, China. BMC Pulm Med. 2024
Apangu T, Acayo S, Atiku LA, et al. Intervention to Stop Transmission of Imported Pneumonic Plague - Uganda, 2019. MMWR Morb Mortal Wkly Rep. 2020
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.